Visual performance of a new multifocal diffractive IOL

Article

Comparative study shows excellent intermediate vision results, high levels of spectacle independence and minimal photic phenoma at night.

Study details

The Diffractiva Diff-aA MIOL is currently under clinical evaluation in a multicentre study in which seven participating University or Private Clinics in France, Austria, UK and Libanon are taking part. A total enrollment of 45 patients (90 eyes) with bilateral cataract and eligible for MIOL implantation has been targeted. Ophthalmic examinations including refraction, monocular and binocular visual acuity for far, intermediate (1 m) and near (40 cm) distances have been scheduled at 1-month, 3-months and 6-months postoperatively. Evaluation of contrast sensitivity and defocus curve has been scheduled at 6 months postoperatively, patient satisfaction (quality-of-life questionnaire) at 3 and 6-months postoperatively.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Thomas Bosshard stands at the Oertli Instruments booth at the ESCRS meeting
Eva Kim, MD, speaks about her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.
© 2023 MJH Life Sciences

All rights reserved.